Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Depigoid Rush Build-up in Allergic Rhinitis and Asthma
NCT01734265Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Nov 2012
- Primary completion
- Mar 2013
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Depigoid in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), asthma, sponsored by LETI Pharma. Started Nov 2012; status: completed.
02
Drugs
Depigoid
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on NCT01734265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734265.